KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EPS (Basic) (2023 - 2025)

Biocryst Pharmaceuticals' EPS (Basic) history spans 9 years, with the latest figure at $1.17 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 1000.0% year-over-year to $1.17; the TTM value through Dec 2025 reached $1.25, up 390.7%, while the annual FY2025 figure was $1.26, 393.02% up from the prior year.
  • EPS (Basic) reached $1.17 in Q4 2025 per BCRX's latest filing, up from $0.06 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.17 in Q4 2025 to a low of -$0.84 in Q4 2023.
  • Average EPS (Basic) over 3 years is -$0.0, with a median of -$0.06 recorded in 2024.
  • Peak YoY movement for EPS (Basic): surged 84.52% in 2024, then surged 1000.0% in 2025.
  • A 3-year view of EPS (Basic) shows it stood at -$0.84 in 2023, then soared by 84.52% to -$0.13 in 2024, then surged by 1000.0% to $1.17 in 2025.
  • Per Business Quant, the three most recent readings for BCRX's EPS (Basic) are $1.17 (Q4 2025), $0.06 (Q3 2025), and $0.02 (Q2 2025).